Brockmeier ConsultingContact

Digital Health Consulting

Digital health consulting from someone who has built it inside pharma.

Independent advisory for pharma and medtech teams, digital health scaleups, early-stage startups, and investors — on the strategy, partnerships, and commercial models that move promising products into real-world use.

What it covers

Pharma partnership readiness

Getting a product and its pitch ready for real pharma evaluation: positioning, finding the right internal champion, and a story that matches how pharma actually funds decisions.

Regulatory + commercial strategy

Building the regulatory pathway (e.g. SaMD classification, EU MDR vs. FDA) and the commercial model together, so one doesn't undercut the other.

Build vs. partner decisions

A structured evaluation of whether to build in-house or partner externally, grounded in what actually gets funded and adopted inside drug-first or device-first organizations.

Device-to-digital strategy

For medtech teams extending a physical product with software or a companion app — and the added regulatory and commercial complexity that comes with it.

Digital health diligence

A domain-expert second opinion for investors on a company's regulatory, commercial, and partnership viability.

Experience

15+ years in engineering and digital health leadership, including over a decade at Novo Nordisk across regulated and unregulated products.

I owned the Diabetes Companion App program end-to-end — strategy, commercialization, partnerships, and team leadership — supporting six brands, integrating with glucose and injection devices, and launching in five markets, within a €4M partnership portfolio I oversaw.

Ways to work together

Workshop

A focused session — half a day to a few days — on one specific challenge.

Advisory

Regular check-ins with leadership and a sounding board for high-stakes decisions.

Embedded

Working inside your team on a regular cadence, as a fractional team member.

Let's talk.

If you're navigating a first pharma partnership, a new regulatory pathway, or a commercial model that needs to hold up — I'd like to hear about it.